​SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results

Released on: Monday, 16 Nov 2026 10:24AM


Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement

IRVINE, Calif., Nov 16 (Bernama-BUSINESS WIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026).

Third Quarter 2026 Financial Highlights
 
Third-quarter results reflected both growth and improved profitability in the core MSO business. Revenue growth was driven by higher management services revenue, including the impact of service fee structure revisions announced in August, as well as the consolidation of Waqoo.

The medical corporations supported by SBC Medical continued to expand. As of September 30, 2026, the clinic network had increased by 36 locations year-over-year to 293 locations2. Patient visits3 over the trailing twelve months totaled 7.06 million, up 9% year-over-year. Average spend per visit was $290, up 4% year-over-year.

Comment from SBC Medical’s Chairman and CEO Yoshiyuki Aikawa:

“The third quarter of 2026 marked a strong reacceleration in SBC Medical’s growth. Revenue increased 35% year-over-year, income from operations rose 66%, and net income attributable to SBC Medical rose 22%, with a net income margin of 27% and an Adjusted EBITDA1 margin of 47%. Following the structural reforms implemented in 2025, growth and profitability are improving in tandem, demonstrating the strength of our highly profitable MSO model.

Our MSO revenue growth is supported by two key levers: expanding our clinic network and increasing service fees per clinic. Our goal is not simply to add locations. We aim to raise productivity and profitability at the clinics we support while expanding the network efficiently. This quarter’s growth in management services revenue, including the effect of service fee revisions, demonstrates progress in this model.

To strengthen this model further, we are investing in AI and technology. Specifically, we are developing a proprietary local large language model (LLM) infrastructure designed to enable the secure use of medical data while optimizing AI costs, while also advancing our clinic operating systems through our capital and business alliance with Atomic Software. Together, these initiatives are intended to improve profitability at existing clinics and make new clinic openings more efficient, enabling our scalable MSO platform to generate greater earnings power as the business expands.

Our Longevity business, which we view as our next growth opportunity, is also making tangible progress. As a first step, we are developing an in-house DNA methylation-based test to estimate biological age, drawing on the Waqoo Group’s research and technology capabilities. By adding diagnostics to our existing medical network and combining AI with physicians’ expertise, we aim to build an integrated platform spanning testing, personalized treatment and evaluation of outcomes.

In Japan, we will continue expanding our multi-brand presence in aesthetic dermatology and broadening our non-aesthetic medical services. Internationally, we are pursuing collaboration with OrangeTwist in the United States and expansion across ASEAN markets. These initiatives are designed to unlock further growth in our existing business while pursuing opportunities in new markets.

For the first nine months of 2026, net cash provided by operating activities totaled $50 million. As of September 30, 2026, we held $198 million in cash and cash equivalents and $154 million in Net Cash4. We intend to deploy this strong financial position toward disciplined growth investment, with the goal of sustaining EPS growth over the medium- to long-term and enhancing corporate value.”

Summary of Key Financials
 
 Unit3Q263Q25YoY9M269M25YoY
Total Revenues$MM5943+35%151134+13%
Net Income Attributable to
SBC Medical
$MM1613+22%3837+2%
Net Income Margin%2730(3)pt2527(2)pt
Adjusted EBITDA 1$MM2817+66%6657+17%
Adjusted EBITDA Margin 1%4738+9pt4442+2pt
ROE (Annualized) 5%2323(0)pt1922(3)pt
Basic EPS 6$0.150.12+25%0.370.36+3%

1 Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP financial measures. For more information on non-GAAP financial measures, please refer to “Use of Non-GAAP Financial Measures” and “Reconciliation of GAAP to Non-GAAP Measures (unaudited).”

2 Represents the total number of locations across the Company’s support and partnership network, including franchised locations of SBC-branded clinics, Rize Clinic, Gorilla Clinic, AHH Clinic and JUN CLINIC, as well as locations operated by OrangeTwist, in which the Company holds a minority equity interest through its equity method investment in OT Midco Holdings, LLC.

3 Patient visits include patients of SBC-branded clinics, Rize Clinic, Gorilla Clinic, AHH Clinic, and JUN CLINIC. The period covered is from October 1, 2025 to September 30, 2026.

4 Net Cash is a non-GAAP financial measure, calculated as cash and cash equivalents ($198 million), less bank and other borrowings and finance lease liabilities, current and non-current ($34 million), and operating lease liabilities, current and non-current ($10 million), each as presented in the unaudited consolidated balance sheet as of September 30, 2026, resulting in Net Cash of $154 million.

5 Return on equity (ROE) is calculated as net income attributable to SBC Medical divided by average shareholders’ equity (beginning and end of period).

6 Basic EPS is calculated as net income attributable to SBC Medical divided by the weighted average number of shares outstanding.

Conference Call

The Company will hold a conference call on Friday, November 13th, 2026 at 08:30 a.m. Eastern Time (or Friday, November 13th, 2026 at 10:30 p.m. Japan Time) to discuss the financial results for the third quarter ended September 30, 2026. A question-and-answer session will follow the prepared remarks.

During the live webcast, participants may submit questions in real-time using the Zoom Q&A button.

All attendees, regardless of their current stock ownership status, are welcome to submit questions. Please note that due to time constraints and the nature of the inquiries, we may not be able to address every question during the call.

Please register in advance of the conference using the link provided below:

https://zoom.us/webinar/register/WN_CLFqOL3XTourhX2qjAJnxw#/registration

Upon registration, you will be able to access the dedicated conference call viewing site.

Additionally, the earnings release, accompanying slides, and a separate link to the archived webcast of this conference call will be available on the Company’s Investor Relations website at https://ir.sbc-holdings.com/.

About SBC Medical

SBC Medical is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.

Company Name: SBC Medical Group Holdings Incorporated | Listed Market: NASDAQ Global Market | Ticker: SBC | Address: 200 Spectrum Center Drive, Suite 300, Irvine, CA 92618 USA | IR Website: https://ir.sbc-holdings.com/ | LinkedIn: https://www.linkedin.com/company/sbc-medical-group-holdings-inc

Use of Non-GAAP Financial Measures

The Company uses non-GAAP measures, such as Adjusted EBITDA, Adjusted EBITDA margin and Net Cash, in evaluating its operating results and financial position and for financial and operational decision-making purposes. The Company believes that the non-GAAP financial measures help identify underlying trends in its business, provide useful information about the Company’s results of operations, enhance the overall understanding of the Company’s past performance and future prospects, and allow for greater visibility with respect to key metrics used by the Company’s management in its financial and operational decision-making. In particular, the Company believes Net Cash is useful to investors in evaluating the Company’s liquidity and financial position, including its capacity to fund growth investments.

The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The presentations of these measures have limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. For reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures, see the reconciliations included at the end of this press release and, for Net Cash, footnote 4 to the “Summary of Key Financials.”

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s plans and strategies for service expansion; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets,” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.
 
SBC MEDICAL GROUP HOLDINGS INCORPORATED
UNAUDITED CONSOLIDATED BALANCE SHEETS
  September 30,
2026
  December 31,
2025
 
ASSETS        
Current assets:        
Cash and cash equivalents $198,428,275  $163,773,838 
Time deposits  4,000,000   — 
Accounts receivable  2,540,219   2,388,021 
Accounts receivable – related parties  30,931,517   27,511,730 
Inventories  2,949,218   2,792,617 
Short-term investments – related parties  318,297   319,193 
Finance lease receivables, current – related parties  16,143,695   12,832,355 
Income tax recoverable  1,292,660   1,175,510 
Customer loans receivable, current  3,966,531   8,705,999 
Prepaid expenses and other current assets  10,762,659   11,724,852 
Prepaid expenses and other receivables – related parties  2,522,970   — 
Total current assets  273,856,041   231,224,115 
         
Non-current assets:        
Property and equipment, net  8,527,530   7,539,392 
Intangible assets, net  45,226,994   47,742,888 
Long-term investments, net  1,880,112   1,299,366 
Equity method investments  19,157,291   20,312,642 
Goodwill, net  15,075,256   15,432,061 
Finance lease receivables, non-current – related parties  14,448,126   13,746,513 
Operating lease right-of-use assets  10,150,912   8,366,569 
Finance lease right-of-use assets  277,827   450,874 
Deferred tax assets  8,000,383   4,014,294 
Customer loans receivable, non-current  2,325,289   4,824,977 
Long-term prepayments  522,473   393,270 
Long-term investments in MCs – related parties  17,787,217   17,837,293 
Other assets  7,587,608   7,263,692 
Total non-current assets  150,967,018   149,223,831 
Total assets $424,823,059  $380,447,946 
         
LIABILITIES AND STOCKHOLDERS’ EQUITY        
         
Current liabilities:        
Accounts payable $23,408,185  $16,988,384 
Accounts payable – related parties  918,135   651,463 
Bank and other borrowings, current  8,757,956   9,099,046 
Advances from customers  877,664   1,415,762 
Advances from customers – related parties  3,600,523   5,357,221 
Income tax payable  16,707,822   8,821,853 
Operating lease liabilities, current  5,754,161   4,416,960 
Finance lease liabilities, current  88,091   132,946 
Accrued liabilities and other current liabilities  14,552,613   11,544,695 
Due to related party  —   2,692,673 
Total current liabilities  74,665,150   61,121,003 
         
Non-current liabilities:        
Bank and other borrowings, non-current  24,845,177   33,734,438 
Deferred tax liabilities  15,614,455   16,374,832 
Operating lease liabilities, non-current  4,541,685   4,136,257 
Finance lease liabilities, non-current  62,857   116,527 
Other liabilities  1,620,786   1,660,183 
Total non-current liabilities  46,684,960   56,022,237 
Total liabilities  121,350,110   117,143,240 
         
Stockholders’ equity:        
Preferred stock ($0.0001 par value, 20,000,000 shares authorized; no shares issued and outstanding as of September 30, 2026 and December 31, 2025)  —   — 
Common stock ($0.0001 par value, 400,000,000 shares authorized, 103,881,251 shares issued, and 102,576,943 shares outstanding as of September 30, 2026 and December 31, 2025)  10,388   10,388 
Additional paid-in capital  75,660,743   72,867,424 
Treasury stock (at cost, 1,304,308 shares as of September 30, 2026 and December 31, 2025)  (7,749,997)  (7,749,997)
Retained earnings  278,142,255   240,448,620 
Accumulated other comprehensive loss  (59,214,802)  (57,294,239)
Total SBC Medical Group Holdings Incorporated stockholders’ equity  286,848,587   248,282,196 
Non-controlling interests  16,624,362   15,022,510 
Total stockholders’ equity  303,472,949   263,304,706 
Total liabilities and stockholders’ equity $424,823,059  $380,447,946 
 
SBC MEDICAL GROUP HOLDINGS INCORPORATED
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
  For the Three Months
Ended September 30,
  For the Nine Months
Ended September 30,
 
  2026  2025  2026  2025  
Revenues, net – related parties $53,518,360  $39,617,548  $135,205,614  $123,819,591  
Revenues, net  5,063,160   3,735,687   15,624,536   10,221,192  
Total revenues, net  58,581,520   43,353,235   150,830,150   134,040,783  
Cost of revenues (including cost of revenues from related parties of $1,749,587 and $4,018,377 for the three months ended September 30, 2026 and 2025, and $2,012,569 and $12,144,907 for the nine months ended September 30, 2026 and 2025, respectively)  16,402,500   12,741,748   42,327,080   35,685,635  
Gross profit  42,179,020   30,611,487   108,503,070   98,355,148  
                  
Operating expenses:                 
Selling, general and administrative expenses (including selling, general and administrative expenses from related parties of $877,328 and $154,063 for the three months ended September 30, 2026 and 2025, and $1,562,231 and $569,830 for the nine months ended September 30, 2026 and 2025, respectively)  15,761,753   14,730,247   45,405,238   43,717,642  
Total operating expenses  15,761,753   14,730,247   45,405,238   43,717,642  
                  
Income from operations  26,417,267   15,881,240   63,097,832   54,637,506  
                  
Other income (expenses):                 
Interest income (including interest income from related parties of $1,582 and nil for the three months ended September 30, 2026 and 2025, and $5,047 and nil for the nine months ended September 30, 2026 and 2025, respectively)  344,937   120,384   474,826   198,599  
Interest expense  (128,878)  (48,635)  (372,313)  (104,493) 
Foreign currency exchange gain (loss), net  (947,087)  923,671   946,850   (904,575) 
Other income (including other income from related parties of nil and $3,069 for the three months ended September 30, 2026 and 2025, and nil and $3,069 for the nine months ended September 30, 2026 and 2025, respectively)  695,294   1,632,527   1,323,914   1,929,258  
Other expenses  —   (2,323)  (678,279)  (1,003,801) 
Gain on redemption of life insurance policies  —   —   —   8,746,138  
Total other income (expenses)  (35,734)  2,625,624   1,694,998   8,861,126  
                  
Income before income taxes and equity in losses of equity method investees  26,381,533   18,506,864   64,792,830   63,498,632  
Income tax expense  (9,378,075)  (5,673,538)  (24,729,409)  (26,733,504) 
Equity in losses of equity method investees, net of tax  (586,699)  —   (1,155,351)  —  
Net income  16,416,759   12,833,326   38,908,070   36,765,128  
Less: net income (loss) attributable to non-controlling interests  724,017   8,690   1,214,435   (20,194) 
Net income attributable to SBC Medical Group Holdings Incorporated $15,692,742  $12,824,636  $37,693,635  $36,785,322  
                  
Other comprehensive income (loss):                 
Foreign currency translation adjustment $7,066,384  $(6,791,961) $(2,502,636) $11,639,635  
Total comprehensive income  23,483,143   6,041,365   36,405,434   48,404,763  
Less: comprehensive income attributable to non-controlling interests  415,698   10,329   632,362   157,908  
Comprehensive income attributable to SBC Medical Group Holdings Incorporated $23,067,445  $6,031,036  $35,773,072  $48,246,855  
                  
Net income per share attributable to SBC Medical Group Holdings Incorporated                 
Basic and diluted $0.15  $0.12  $0.37  $0.36  
Weighted average shares outstanding                 
Basic and diluted  102,576,943   102,642,634   102,576,943   103,139,851  
 
SBC MEDICAL GROUP HOLDINGS INCORPORATED
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
  For the Nine Months
Ended September 30,
 
  2026  2025 
CASH FLOWS FROM OPERATING ACTIVITIES        
Net income $38,908,070  $36,765,128 
Adjustments to reconcile net income to net cash provided by (used in) operating activities:        
Depreciation and amortization expense  2,979,917   2,010,616 
Non-cash lease expense  4,239,772   3,436,789 
Provision for (reversal of) credit losses  (22,236)  305,963 
Equity in losses of equity method investees  1,155,351   — 
Stock-based compensation  19,541   — 
Fair value change of long-term investments  (579,154)  (724,476)
Gain on redemption of life insurance policies  —   (8,746,138)
Loss (gain) on disposal of property and equipment  9,375   (414,167)
Change in fair value of cryptocurrencies  —   (146,036)
Deferred income taxes  (4,386,410)  9,104,235 
Changes in operating assets and liabilities:        
Accounts receivable  (197,484)  (1,084,316)
Accounts receivable – related parties  (3,502,443)  (28,031,690)
Inventories  (191,314)  265,052 
Finance lease receivables – related parties  (4,050,925)  (9,227,612)
Customer loans receivable  7,158,848   12,153,263 
Prepaid expenses and other current assets  923,442   (2,180,695)
Prepaid expenses and other receivables – related parties  (2,500,352)  — 
Long-term prepayments  (375,662)  281,666 
Other assets  (390,302)  77,609 
Accounts payable  6,551,564   2,549,938 
Accounts payable – related parties  280,593   2,144,314 
Notes payable – related parties  —   (12,759,536)
Advances from customers  (528,982)  161,165 
Advances from customers – related parties  (1,726,044)  (5,470,844)
Income tax payable  7,711,189   (19,936,155)
Operating lease liabilities  (4,279,802)  (3,639,887)
Accrued liabilities and other current liabilities  3,059,724   (4,096,471)
Other liabilities  (18,888)  (93,141)
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES  50,247,388   (27,295,426)
         
CASH FLOWS FROM INVESTING ACTIVITIES        
Purchase of property and equipment  (1,214,421)  (603,484)
Prepayments for property and equipment  (888,098)  (838,568)
Payments made on behalf of related parties  —   (1,840,801)
Purchase of long-term investments  —   (654,070)
Placement of time deposits  (4,000,000)  — 
Purchase of cryptocurrencies  —   (424,250)
Cash paid for acquisition of subsidiaries, net of cash acquired  —   (14,861,858)
Long-term loans to others  —   (14,514)
Repayments from related parties  —   1,911,440 
Repayments from others  41,765   73,928 
Proceeds from redemption of life insurance policies  —   17,735,717 
Deconsolidation of VIE, net of cash disposed of  1,019,909   — 
Proceeds from disposal of property and equipment  —   2,755,983 
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES  (5,040,845)  3,239,523 
         
CASH FLOWS FROM FINANCING ACTIVITIES        
Borrowings from bank and others  —   14,851,980 
Borrowings from related parties  —   15,000 
Proceeds from exercise of stock acquisition rights in subsidiary by non-controlling interests  94,843   — 
Repayments of bank and other borrowings  (8,912,553)  (721,874)
Repayments of finance lease liabilities  (99,932)  (310,603)
Repayments to related parties  (22,657)  (46,782)
Repurchase of common stock  —   (4,999,997)
Deemed contribution in connection with price modification on disposal of property and equipment  —   9,682,277 
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES  (8,940,299)  18,470,001 
         
Effect of exchange rate changes  (1,611,807)  7,973,128 
         
NET CHANGE IN CASH AND CASH EQUIVALENTS  34,654,437   2,387,226 
CASH AND CASH EQUIVALENTS AS OF THE BEGINNING OF THE PERIOD  163,773,838   125,044,092 
CASH AND CASH EQUIVALENTS AS OF THE END OF THE PERIOD $198,428,275  $127,431,318 
         
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION        
Cash paid for interest expense $372,313  $104,493 
Cash paid for income taxes, net $21,135,092  $37,555,740 
         
NON-CASH INVESTING AND FINANCING ACTIVITIES        
Property and equipment transferred from prepaid expenses $57,013  $— 
Property and equipment transferred from long-term prepayments $1,050,946  $1,428,254 
Operating lease right-of-use assets obtained in exchange for operating lease liabilities $221,443  $105,556 
Finance lease right-of-use assets obtained in exchange for finance lease liabilities $—  $612,466 
Remeasurement of operating lease liabilities and right-of-use assets due to lease modifications $5,845,817  $2,646,028 
Payables to related parties in connection with loan services provided $—  $14,362,902 
Issuance of common stock as incentive shares $—  $86 
 
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (UNAUDITED)
SBC MEDICAL GROUP HOLDINGS INCORPORATED
   For the Three Months Ended
September 30,
    For the Nine Months Ended
September 30,
 
   2026    2025    2026   2025 
Total revenues, net  $58,581,520    $43,353,235    $150,830,150   $134,040,783 
Net income attributable to SBC Medical Group Holdings Incorporated   15,692,742     12,824,636     37,693,635    36,785,322 
Adjusted to add (deduct) the following:                      
Net income (loss) attributable to non-controlling interests   724,017     8,690     1,214,435    (20,194)
Equity in losses of equity method investees, net of tax   586,699     —     1,155,351    — 
Income tax expense   9,378,075     5,673,538     24,729,409    26,733,504 
Gain on redemption of life insurance policies   —     —     —    (8,746,138)
Other expenses   —     2,323     678,279    1,003,801 
Other income   (695,294)    (1,632,527)    (1,323,914)   (1,929,258)
Foreign currency exchange loss (gain), net   947,087     (923,671)    (946,850)   904,575 
Interest expense   128,878     48,635     372,313    104,493 
Interest income   (344,937)    (120,384)    (474,826)   (198,599)
Depreciation and amortization expense   1,176,959     746,211     2,979,917    2,010,616 
 Adjusted EBITDA  $27,594,226    $16,627,451    $66,077,749   $56,648,122 
 Net income margin   27%    30%    25%   27%
 Adjusted EBITDA margin   47%    38%    44%   42%

Adjusted EBITDA is a non-GAAP financial measure defined as net income attributable to SBC Medical adjusted for net income (loss) attributable to non-controlling interests, equity in losses of equity method investees, net of tax, income tax expense, gain on redemption of life insurance policies, other expenses, other income, foreign currency exchange loss (gain), net, interest expense, interest income, and depreciation and amortization expense.

Net income margin is defined as net income attributable to SBC Medical divided by total revenues, net. Adjusted EBITDA margin is defined as Adjusted EBITDA divided by total revenues, net.

View source version on businesswire.com:
https://www.businesswire.com/news/home/20261113831653/en/

Contact

SBC Medical Group Holdings Incorporated — Hikaru Fukui / Head of IR Department; E-mail: ir@sbc-holdings.com

Source : SBC Medical Group Holdings Incorporated

--BERNAMA
 
Back to Home